Real-World Evidence of Off-Label Use of Commercially Automated Insulin Delivery Systems Compared to Multiple Daily Insulin Injections in Pregnancies Complicated by Type 1 Diabetes

Abstract

Aims:

To compare glycemic control and maternal–fetal outcomes of women with type 1 diabetes (T1D) using hybrid closed loop (HCL) versus multiple daily insulin injections (MDI) plus continuous glucose monitoring.

Methods:

Multicenter prospective cohort study of pregnant women with T1D in Spain. We evaluated HbA1c and time spent within (TIR), below (TBR), and above (TAR) the pregnancy-specific glucose range of 3.5–7.8 mmol/L. Adjusted models were performed for adverse pregnancy outcomes, including baseline maternal characteristics and center.

Results:

One hundred twelve women were included (HCL n = 59). Women in the HCL group had a longer duration of diabetes and higher rates of prepregnancy care. There was no between-group difference in HbA1c in any trimester. However, in the second trimester, MDI users had a greater decrease in HbA1c (−6.12 ± 9.06 vs. −2.16 ± 7.42 mmol/mol, P = 0.031). No difference in TIR (3.5–7.8 mmol/L) and TAR was observed between HCL and MDI users, but with a higher total insulin dose in the second trimester [+0.13 IU/kg·day)]. HCL therapy was associated with increased maternal weight gain during pregnancy (β_adjusted = 3.20 kg, 95% confidence interval [CI] 0.90–5.50). Regarding neonatal outcomes, newborns of HCL users were more likely to have higher birthweight (β_adjusted = 279.0 g, 95% CI 39.5–518.5) and macrosomia (OR_adjusted = 3.18, 95% CI 1.05–9.67) compared to MDI users. These associations disappeared when maternal weight gain or third trimester HbA1c was included in the models.

Conclusions:

In a real-world setting, HCL users gained more weight during pregnancy and had larger newborns than MDI users, while achieving similar glycemic control in terms of HbA1c and TIR.